IntegraGen presented positive clinical results on its miR-31-3p biomarker during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago. The data presented demonstrates that IntegraGen’s proprietary miR-31-3p biomarker is predictive for both survival and treatment response in patients receiving anti-EGFR therapy.

These results are based on an analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial. The data presented, which was featured during the colorectal cancer poster discussion session, represents the first study comparing miR-31-3p expression in mCRC patients treated in first line with anti-EGFR vs. anti-VEGF therapy.